Ono’s Phase 3 Sapablursen Trial Targets Polycythemia Vera Upside for OPHLF Investors

ONO Pharmaceutical Co (OPHLF) announced an update on their ongoing clinical study.

The Phase 3 study titled “A Phase 3 Randomized, Double-blind, Placebo-controlled Global Study of Sapablursen in Polycythemia Vera” aims to test a new add-on treatment for this chronic blood cancer. It focuses on how safe and effective sapablursen is when used with today’s standard care, which matters for long-term disease control and quality of life.

Sapablursen, also called ONO-0530 or ISIS 702843, is an injectable drug given under the skin. It is designed to work alongside current therapies to help better manage polycythemia vera and reduce the need for frequent blood draws or other intensive measures.

The trial is interventional and Phase 3, with patients randomly assigned to different groups. It uses a parallel design with double-blind masking, so neither participants nor investigators know who gets sapablursen or placebo at first, and the main goal is to evaluate treatment benefit.

The study runs in three parts, starting with a blinded phase and moving into open-label and long-term extension periods lasting up to 156 weeks. It was first submitted on 18 February 2026, with the most recent update filed on 6 May 2026, signaling active set-up and recruitment efforts.

For investors, this update highlights Ono Pharmaceutical’s push into rare blood disorders, an area where steady demand and limited options can support premium pricing. Success could strengthen ONO’s pipeline value and sentiment for OPHLF, while raising competitive pressure on incumbents in the myeloproliferative space, including firms developing JAK inhibitors and other novel agents.

The trial remains ongoing and actively updated, and investors can track further details and milestones on the ClinicalTrials portal.

To learn more about OPHLF’s potential, visit the ONO Pharmaceutical Co drug pipeline page.